{"result":"ok","result_detail":"
<\/div>

Webinar – Monoclonal Antibody Analysis Using mAbXmise\u00ae Kits and Xevo TQ Absolute XR Mass Spectrometer<\/h2>

Discover practical approaches for developing robust monoclonal antibody (mAb) and anti-drug antibody (ADA) workflows using LC-MS\/MS, and discover how ready-to-use solutions can help simplify assay implementation.\r\n\r\nDuring this webinar you'll learn how to:\r\n- Accelerate assay implementation,\r\n- Reduce matrix interferences through peptide-level detection,\r\n- Support multiplex mAb and ADA quantification,\r\n- Improve workflow consistency and analytical confidence,\r\n- Leverage the performance of the Xevo\u2122 TQ Absolute XR Mass Spectrometer for reliable biologic analysis.\r\n\r\nThis webinar is presented by Martien Van Der Meijden, from WATERS EU Clinical Support Team, and Dorothee Lebert, Chief Scientific Officer at Promise Proteomics.<\/p><\/div><\/a><\/a><\/div>

<\/div>

MSACL2026 – Poster ARUP labs & PROMISE Proteomics on inflammation mAbs & ADAs<\/h2>

This poster, presented by Amol Bajaj at MSACL 2026, deals with the use of mAbXmise kits to quantify VDZ and USTE drug-mAbs and associated antidrug antibodies, using LC-MS\/MS.<\/p><\/div><\/a><\/a><\/div>

<\/div>

IATDMCT2026 – PharmacoFlash & Poster<\/h2>

Pharmacoflash presentation & associated poster, presented at IATDMCT2026<\/p><\/div><\/a><\/a><\/div>

<\/div>

Analytical Strategy for LC-MS Quantification of Enfortumab and Free MMAE in Plasma from Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin<\/h2>

In this poster, the main objective is to develop a quantitative LC-MS\/MS assay for measuring both the total antibody and the released payload, with the aim of providing a tool to improve patient safety and predict treatment related toxicities.\r\nIt is applied to Enfortumab Vedotin.<\/p><\/div><\/a><\/a><\/div>

<\/div>

Application Note: mAbs Testing in Inflammation Using Mass Spectrometry \u2013 Combination of mAbXmise™ Kits and XEVO™ TQ Absolute XR Mass Spectrometer<\/h2>

Davor Fielitz, Doroth\u00e9e Lebert<\/p><\/div><\/a><\/a><\/div>

<\/div>

Early Assessment of Circulating Tumor Cells and Their PD-L1 2 Expression as Predictive Biomarkers in Metastatic Non-Small Cell 3 Lung Cancer patients treated with Immunotherapy<\/h2>

Grolleau, E., Barthelemy, D., Millet, A., Calatini, S., Lescuyer, G., Komaroff, A., Benzerdjeb, N., Lebert, D., Piecyk, M., Guitton, J., Couraud, S., Payen, L. (2026). Early Assessment of Circulating Tumor Cells and Their PD-L1 2 Expression as Predictive Biomarkers in Metastatic Non-Small Cell 3 Lung Cancer patients treated with Immunotherapy. SSRN. http:\/\/dx.doi.org\/10.2139\/ssrn.6042939\r\n\r\n<\/p><\/div><\/a><\/a><\/div>

<\/div>

Development of a Novel Liquid Chromatography Coupled to Multiple Reaction Monitoring (LC-MRM) Assay for the Quantification of Neurofilament Light Chain in Cerebrospinal Fluid and Comparison with Ultra-Sensitive Immunoassay: A Step toward Standardization<\/h2>

Coppens, S., Vialaret, J., Mond\u00e9sert, E., Drinkwater, G., Luckau, L., Lehmann, S., Hirtz, C. (2026). Development of a Novel Liquid Chromatography Coupled to Multiple Reaction Monitoring (LC-MRM) Assay for the Quantification of Neurofilament Light Chain in Cerebrospinal Fluid and Comparison with Ultra-Sensitive Immunoassay: A Step toward Standardization. Clinical Chemistry, hvaf180. https:\/\/doi.org\/10.1093\/clinchem\/hvaf180<\/p><\/div><\/a><\/a><\/div>

<\/div>

Neurofilament Light Chain under the Lens of Structural Mass Spectrometry<\/h2>

Coppens, S., Gogishvili, D., Faustinelli, V., Scollo, E., Hopley, C., Abeln, S., Dalby, P., Goenaga-Infante, H., Luckau, L., Vialaret, J., Lehmann, S., Hirtz, C., Illes-Toth, E. (2025). Neurofilament Light Chain under the Lens of Structural Mass Spectrometry. ACS Chemical Neuroscience, 16, 141\u2013151. doi: 10.1021\/acschemneuro.4c00526<\/p><\/div><\/a><\/a><\/div>

<\/div>

A Candidate Reference Measurement Procedure for the Quantification of \u03b1-synuclein in Cerebrospinal Fluid using an SI Traceable Primary Calibrator and Multiple Reaction Monitoring<\/h2>

Zhang, L., Illes-Toth, E., Cryar, A., Drinkwater, G., Di Vagno, L., Pons, M.-L., Mateyka, J., McCullough, B., Achtar, E., Clarkson, C., G\u00f6schel, L., K\u00f6rtv\u00e9lyessy, P., Mussell, C., Hopley, C. J., Fl\u00f6el, A., Hirtz, C., Lehmann, S., Quaglia, M. (2024). A Candidate Reference Measurement Procedure for the Quantification of \u03b1-synuclein in Cerebrospinal Fluid using an SI Traceable Primary Calibrator and Multiple Reaction Monitoring. Analyst, 149, 4842. DOI: 10.1039\/d4an00634h<\/p><\/div><\/a><\/a><\/div>

<\/div>

CSF Neurofilament Light Chain Profiling and Quantitation in Neurological Diseases<\/h2>

Leckey, C. A., Coulton, J. B., Giovannucci, T. A., He, Y., Aslanyan, A., Laban, R., Heslegrave, A., Doykov, I., Ammoscato, F., Chataway, J., De Angelis, F., Gnanapavan, S., Byrne, L. M., Schott, J. M., Wild, E. J., Barthel\u00e9my, N. R., Zetterberg, H., Wray, S., Bateman, R. J., Mills, K., Paterson, R. W. (2024). CSF Neurofilament Light Chain Profiling and Quantitation in Neurological Diseases. Brain Communications, Volume 6, Issue 3, fcae132. https:\/\/doi.org\/10.1093\/braincomms\/fcae132<\/p><\/div><\/a><\/a><\/div>

<\/div>

B-155 Analysis of Monoclonal Antibodies Using a Quantification LC-MS\/MS Kit – Spotlight on Infliximab<\/h2>

Calton, L., Lebert, D., Foley, D. (2024). B-155 Analysis of Monoclonal Antibodies Using a Quantification LC-MS\/MS Kit - Spotlight on Infliximab. Clinical Chemistry, Volume 70, hvae106.515. https:\/\/doi.org\/10.1093\/clinchem\/hvae106.515<\/p><\/div><\/a><\/a><\/div>

<\/div>

B-162 Evaluation of Two Commercially Available Stable Isotope Labeled Whole-Protein Infliximab as Internal Standard for a Clinical Infliximab LC-MS\/MS Assay<\/h2>

McShane, A., Zhong B., Gosser L., Abonamah J., Payto D. (2024). B-162 Evaluation of Two Commercially Available Stable Isotope Labeled Whole-Protein Infliximab as Internal Standard for a Clinical Infliximab LC-MS\/MS Assay. Clinical Chemistry, Volume 70, hvae106.522. https:\/\/doi.org\/10.1093\/clinchem\/hvae106.522<\/p><\/div><\/a><\/a><\/div>

<\/div>

Webinar: Monoclonal Antibody Analysis using mAbXmise kits and Xevo TQ Absolute XR Mass spectrometer<\/h2>

Monoclonal antibodies (mAbs) analysis can be a challenging. Learn how to streamline mAbs analysis with a workflow that improves robustness and throughput when you participate in our live presentation Monoclonal Antibody Analysis Using mAbXmise\u00ae Kits and Xevo TQ Absolute XR Mass Spectrometer. \r\n\r\nIn this live webinar, you'll learn how our senior scientists:\r\n- Rapidly implemented this workflow with ready-to-use kits to simplify method setup\r\n- Achieved high selectivity and peptide level detection to avoid matrix interferences common in immunoassays\r\n- Enabled multiplex quantification of multiple mAbs or anti-drug antibodies (ADAs) in a single run thanks to the broad dynamic range\r\n- Corrected for sample and analytical variability using internal standards, improving inter-lab standardization\r\n\r\n<\/p><\/div><\/a><\/a><\/div>

<\/div>

Exposure response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma ( mRCC ) from the randomised phase 2 BIONIKK study<\/h2>

B. Blanchet, A. Puszkiel, A. Jouinot, M. Bennamoun, D. Maillet, D. Borchiellini, B. Laguerre, D. Pannier, M. Gross Goupil, C. Chevreau, P. Barth\u00e9l\u00e9my, C. Tournigand, E. Coquan, G. Gravis, S. Kotti, W.H. Fridman,\r\nC. Sautes Fridman, S. Oudard, C. Sun, Y. Vano<\/p><\/div><\/a><\/a><\/div>

<\/div>

Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases<\/h2>

Rietveld, P. C., Guchelaar, N. A., Van Eerden, R. A., De Boer, N. L., De Bruijn, P., Sassen, S. D., Madsen, E. V., Koch, B. C., Verhoef, C., Burger, J. W., Mathijssen, R. H., & Koolen, S. L. (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomedicine & Pharmacotherapy, 176, 116820. https:\/\/doi.org\/10.1016\/j.biopha.2024.116820<\/p><\/div><\/a><\/a><\/div>

<\/div>

mAbXmise Tutorial Video<\/h2>

Video tutorial of mAbXmise TDM sample preparation\r\nThe mAbXmise range of kits have been designed to facilitate the implementation in the clinical lab of Promise technology for quantifying monoclonal antibodies (mAbs). mAbXmise kits are ready-to-use kits, containing everything required to prepare the patient sample until the LC-MS injection.<\/p><\/div><\/a><\/a><\/div>

<\/div>

Development and validation of CE-IVD kit for monitoring monoclonal antibodies using mass spectrometry<\/h2>

Pauline Bros, J\u00e9r\u00f4me Chenau, Mathieu Trauchessec &Doroth\u00e9e Lebert<\/p><\/div><\/a><\/a><\/div>

<\/div>

Development of a ready to use LC MS kit for quantifying mAbs plasma levels in patients with cancer, and cross validation of this multiplex solution<\/h2>

Clemence Marin, Nihel Khoudour, Aurelien Millet, Dorothee Lebert, Pauline Bros, Fabienne Thomas, David Ternant, Bruno Lacarelle, Jerome Guitton, Joseph Ciccolini and Benoit Blanchet<\/p><\/div><\/a><\/a><\/div>

<\/div>

Development of a LC-MS\/MS kit for monitoring 7 monoclonal antibodies prescribed in the management of inflammatory diseases<\/h2>

Pauline Bros, Sandrine Bagnos, Doroth\u00e9e Lebert<\/p><\/div><\/a><\/a><\/div>

<\/div>

Development and validation of a LC-MS\/MS kit for monitoring Emicizumab<\/h2>

Agathe Mi\u00e8le, Maud Tengo, Doroth\u00e9e Lebert, Mathieu Trauchessec<\/p><\/div><\/a><\/a><\/div>

<\/div>

Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients<\/h2>

Puszkiel, A., Bianconi, G., Pasquiers, B., Balakirouchenane, D., Arrondeau, J., Boudou-Rouquette, P., Bretagne, M., Salem, J., Decl\u00e8ves, X., Vidal, M., Kramkimel, N., Guegan, S., Aractingi, S., Huillard, O., Alexandre, J., Wislez, M., Goldwasser, F., & Blanchet, B. (2024). British Journal Of Cancer. https:\/\/doi.org\/10.1038\/s41416-024-02659-x<\/p><\/div><\/a><\/a><\/div>

<\/div>

Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients<\/h2>

Marolleau, S., Mogenet, A., Boeri, C., Hamimed, M., Ciccolini, J., & Greillier, L. (2023). CPT : Pharmacometrics & Systems Pharmacology, 12(11), 1795\u20111803. https:\/\/doi.org\/10.1002\/psp4.13063<\/p><\/div><\/a><\/a><\/div>

<\/div>

Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitides During Rituximab Maintenance Therapy<\/h2>

Khoudour, N., Delestre, F., Jabot\u2010Hanin, F., Jouinot, A., Nectoux, J., Letouneur, F., Izac, B., Vidal, M., Guillevin, L., Pu\u00e9chal, X., Charles, P., Terrier, B., & Blanchet, B. (2023). Arthritis & Rheumatology, 75(11), 2003\u20112013. https:\/\/doi.org\/10.1002\/art.42556<\/p><\/div><\/a><\/a><\/div>

<\/div>

Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A<\/h2>

Josset, L., Leuci, A., Janbain, M., De-Wreede, A., Desage, S., Lienhart, A., Bin, V., Lambert, D., Delavenne, X., & Dargaud, Y. (2024). Journal Of Thrombosis And Haemostasis. https:\/\/doi.org\/10.1016\/j.jtha.2024.03.022<\/p><\/div><\/a><\/a><\/div>

<\/div>

Life\u2011threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?<\/h2>

Hamimed, M., Devillier, R., Weiller, P., Marin, C., Schiano, J., Belmecheri, N., Etienne-Grimaldi, M., Ciccolini, J., & Harbi, S. (2023). Cancer Chemotherapy And Pharmacology. https:\/\/doi.org\/10.1007\/s00280-023-04611-x<\/p><\/div><\/a><\/a><\/div>

<\/div>

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis<\/h2>

Ernst, S. M., Hofman, M. M., Van Der Horst, T. E., Paats, M. S., Heijboer, F. W., Aerts, J. G., Dumoulin, D. W., Cornelissen, R., Von Der Th\u00fcsen, J. H., De Bruijn, P., Hoop, E. O., Mathijssen, R. H., Koolen, S. L., & Dingemans, A. C. (2024). EBioMedicine, 102, 105074. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105074<\/p><\/div><\/a><\/a><\/div>

<\/div>

Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods<\/h2>

Tron, C., Lemaitre, F., Bros, P., Goulvestre, C., Franck, B., Mouton, N., Bagnos, S., Coriat, R., Khoudour, N., Lebert, D., & Blanchet, B. (2022). Bioanalysis, 14(11), 831\u2011844. https:\/\/doi.org\/10.4155\/bio-2022-0057<\/p><\/div><\/a><\/a><\/div>

<\/div>

Cross-Validation of a Multiplex LC-MS\/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study<\/h2>

Marin, C., Khoudour, N., Millet, A., Lebert, D., Bros, P., Thomas, F., Ternant, D., Lacarelle, B., Guitton, J., Ciccolini, J., & Blanchet, B. (2021). Pharmaceuticals, 14(8), 796. https:\/\/doi.org\/10.3390\/ph14080796<\/p><\/div><\/a><\/a><\/div>

<\/div>

A Validated LC-MS\/MS Method for Performing Belatacept Drug Monitoring in Renal Transplantation<\/h2>

Chhun, S., Trauchessec, M., Melicine, S., Nicolas, F., Miele, A., Lukic, S., Vilain, E., Amrouche, L., Lebert, D., Anglicheau, D., Tartour, E., & Zuber, J. (2023). Biomedicines, 11(11), 2955. https:\/\/doi.org\/10.3390\/biomedicines11112955<\/p><\/div><\/a><\/a><\/div>

<\/div>

Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC\u2010MS\/HRMS and LC\u2010MS\/MS) for the Quantification of Rituximab in Human Plasma<\/h2>

Millet, A., Khoudour, N., Lebert, D., Machon, C., Terrier, B., Blanchet, B., & Guitton, J. (2021). Molecules\/Molecules Online\/Molecules Annual, 26(5), 1383. https:\/\/doi.org\/10.3390\/molecules26051383<\/p><\/div><\/a><\/a><\/div>

<\/div>

Analysis of Pembrolizumab in Human Plasma by LC-MS\/HRMS. Method Validation and Comparison with Elisa<\/h2>

Millet, A., Khoudour, N., Guitton, J., Lebert, D., Goldwasser, F., Blanchet, B., & Machon, C. (2021). Biomedicines, 9(6), 621. https:\/\/doi.org\/10.3390\/biomedicines9060621<\/p><\/div><\/a><\/a><\/div>

<\/div>

Quantification of nivolumab in human plasma by LC-MS\/HRMS and LC-MS\/MS, comparison with ELISA<\/h2>

Millet, A., Khoudour, N., Bros, P., Lebert, D., Picard, G., Machon, C., Goldwasser, F., Blanchet, B., & Guitton, J. (2021). Talanta, 224, 121889. https:\/\/doi.org\/10.1016\/j.talanta.2020.121889<\/p><\/div><\/a><\/a><\/div>

<\/div>

Determination of Cetuximab in Plasma by Liquid Chromatography\u2013High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal Standard<\/h2>

Millet, A., Lebert, D., Picard, G., You, B., Ceruse, P., & Guitton, J. (2019). Therapeutic Drug Monitoring, 41(4), 467\u2011475. https:\/\/doi.org\/10.1097\/ftd.0000000000000613<\/p><\/div><\/a><\/a><\/div>

<\/div>

Infliximab Therapeutic monitoring by tryptic peptide LC-MS\/MS method improvements lead to improved accuracy with decreased imprecision and turnaround time<\/h2>

Ladwig, P. M., Rivard, A. L., Barbeln, A., Maus, A., Murray, D. L., Snyder, M. R., & Willrich, M. A. (2024). Journal Of Mass Spectrometry And Advances In The Clinical Lab. https:\/\/doi.org\/10.1016\/j.jmsacl.2024.01.007<\/p><\/div><\/a><\/a><\/div>

<\/div>

Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?<\/h2>

Jourdil, J., Lebert, D., Gautier-Veyret, E., Lemaitre, F., Bonaz, B., Picard, G., Tonini, J., & Stanke-Labesque, F. (2016). Analytical And Bioanalytical Chemistry\/Analytical & Bioanalytical Chemistry, 409(5), 1195\u20111205. https:\/\/doi.org\/10.1007\/s00216-016-0045-4<\/p><\/div><\/a><\/a><\/div>

<\/div>

Development and validation of quantitative LC-MS\/MS kit for monitoring Eculizumab & Ravulizumab<\/h2>

Agathe Mi\u00e8le, Maud Tengo, Doroth\u00e9e Lebert, Mathieu Trauchessec<\/p><\/div><\/a><\/a><\/div>

<\/div>

Belatacept in renal transplantation: a real-world pharmacokinetic study<\/h2>

St\u00e9phanie Chhun, Sophie Melicine ,Fr\u00e9d\u00e9ric Nicolas, Doroth\u00e9e Lebert, Mathieu Trauchessec, Srboljub Lukic, Estelle Vilain, Lucile Amrouche, Dany Anglicheau, Eric Tartour, Julien Zuber<\/p><\/div><\/a><\/a><\/div>

<\/div>

Simultaneous quantification of infliximab and adalimumab in human plasma by liquid chromatography tandem mass spectrometry using ready to use kit and comparison with two ELISA methods<\/h2>

Camille Tron, Florian Lemaitre, Pauline Bros, Claire Goulvestre, Benedicte Franck, Nicolas Mouton, Sandrine Bagnos, Romain Coriat, Nihel Khoudour, Doroth\u00e9e Lebert and Benoit Blanchet<\/p><\/div><\/a><\/a><\/div>

<\/div>

Quantification of Infliximab and Adalimumab and their anti drug antibodies in human plasma by liquid chromatography tandem mass spectrometry using ready to use kits<\/h2>

Pauline Bros, J\u00e9r\u00f4me Chenau, Sandrine Bagnos, Sigrid Baumgarten, Doroth\u00e9e Lebert<\/p><\/div><\/a><\/a><\/div>

<\/div>

LC-MS\/MS analysis of mAbs using a monoclonal antibodies quantification kit – Spotlight on Infliximab<\/h2>

Dominic Foley, John Vukovic, Doroth\u00e9e Lebert, Lisa J Calton<\/p><\/div><\/a><\/a><\/div>

<\/div>

LC-MS\/MS Analysis of mAbs Using a mabs quantification kit – Spotlight on Infliximab<\/h2>

Dominic Foley, Doroth\u00e9e Lebert, Lisa J. Calton<\/p><\/div><\/a><\/a><\/div>

<\/div>

Streamlined workflow for absolute quantitation of therapeutic monoclonal antibodies using Promise Proteomics mAbXmise kits and a TSQ Altis Plus mass spectrometer<\/h2>

Yvonne E. Song, Dorothee Lebert, Jean-Valery Guillaubez, Stephanie Samra, Edward Goucher, Bradley Hart<\/p><\/div><\/a><\/a><\/div>

<\/div>

Quantification of infliximab and adalimumab in human plasma by LC-MS using a standardized kit-based approach<\/h2>

Pauline Bros, Sandrine Bagnos, Guillaume Picard, Dan Blake, Jack Steed and Doroth\u00e9e Lebert, Promise Proteomics; SCIEX, France; SCIEX, UK<\/p><\/div><\/a><\/a><\/div>

<\/div>

mAbXmise Sales Catalog<\/h2>

The mAbXmise quantification kit is intended to monitor the concentration of therapeutic monoclonal antibodies (mAbs) in samples from patients treated with these mAbs. The kit is a quantitative assay.\r\nmAbXmise kits are based on LC-MS\/MS technology.<\/p><\/div><\/a><\/a><\/div>

<\/div>

SIL-mAbs Catalog<\/h2>

Promise Proteomics has developed a range of solutions to address the needs of bioanalytical scientists. Our stable-isotopically-labelled mAbs (SIL-mAbs) are used as internal standards in quantification assays. They are produced in our ISO9001 certified facility in Grenoble, France.\r\nOur SIL-products are produced in dedicated expression systems with protocols specifically developed and optimized by Promise Proteomics team to ensure high isotopic incorporation, (>98%), high purity (>95%) and stability.<\/p><\/div><\/a><\/a><\/div>

<\/div>

SIL-Proteins Catalog<\/h2>

Promise Proteomics has developed a range of solutions to address the needs of bioanalytical scientists. Our stable-isotopically-labelled proteins (SIL-proteins) are used as internal standards in quantification assays. They are produced in our ISO9001 certified facility in Grenoble, France.\r\nOur SIL-products are produced in dedicated expression systems with protocols specifically developed and optimized by Promise Proteomics team to ensure high isotopic incorporation, (>98%), high purity (>95%) and stability.<\/p><\/div><\/a><\/a><\/div>

<\/div>

DIGESTIF Catalog<\/h2>

DIGESTIF is a two-in-one quality control reagent used to check digestion quality & efficiency as well as LC-MS performances during bottom-up proteomic experiments.<\/p><\/div><\/a><\/a><\/div>"}